Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Aldoxorubicin HCl (formerly MC-DOXHZN; INNO-206; Doxo-EMCH; INNO206), the hydrochloride salt of Aldoxorubicin, is a albumin-binding prodrug of doxorubicin (an anthracycline antibiotic anticancer drug, and a DNA topoisomerase II inhibitor). It is a doxorubicin conjugate that CytRx developed with a tumor as its target. Aldoxorubicin is specifically doxorubicin's (6-maleimidocaproyl) hydrazone. This chemical name basically refers to doxorubicin coupled to N-ε-maleimidocaproic acid hydrazide, or EMCH, an acid-sensitive linker. Aldoxorubicin quickly binds endogenous circulating albumin via the EMCH linker following administration. The accumulation of circulating albumin is preferential in tumors, and it does not enter the bone marrow, heart, or gastrointestinal tract, among other non-specific sites. When albumin-bound aldoxorubicin enters the tumor, its acidic environment causes the acid-sensitive linker to break. The tumor's location releases free doxorubicin.
Targets |
Topoisomerase II; Daunorubicins/Doxorubicins
|
---|---|
References |
Molecular Formula |
C37H43CLN4O13
|
---|---|
Molecular Weight |
787.209329843521
|
Elemental Analysis |
C, 56.45; H, 5.51; Cl, 4.50; N, 7.12; O, 26.42
|
CAS # |
480998-12-7
|
Related CAS # |
Aldoxorubicin;1361644-26-9;MC-DOXHZN;151038-96-9
|
Appearance |
Red solid powder
|
SMILES |
C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(/C(=N/NC(=O)CCCCCN6C(=O)C=CC6=O)/CO)O)N)O.Cl
|
InChi Key |
NGKHWQPYPXRQTM-UKFSEGPMSA-N
|
InChi Code |
InChI=1S/C37H42N4O13.ClH/c1-17-32(46)20(38)13-27(53-17)54-22-15-37(51,23(16-42)39-40-24(43)9-4-3-5-12-41-25(44)10-11-26(41)45)14-19-29(22)36(50)31-30(34(19)48)33(47)18-7-6-8-21(52-2)28(18)35(31)49;/h6-8,10-11,17,20,22,27,32,42,46,48,50-51H,3-5,9,12-16,38H2,1-2H3,(H,40,43);1H/b39-23+;/t17-,20-,22-,27-,32+,37-;/m0./s1
|
Chemical Name |
N-[(E)-[1-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide;hydrochloride
|
Synonyms |
INNO-206 HCl; MC-DOXHZN hydrochloride; INNO206; DOXO-EMCH; EMCH-Doxo; EMCH-doxorubicin; INNO-206; INNO 206; Aldoxorubicin.
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~25 mg/mL (~31.8 mM)
H2O: ~12.5 mg/mL (~15.9 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (2.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (2.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.2703 mL | 6.3515 mL | 12.7031 mL | |
5 mM | 0.2541 mL | 1.2703 mL | 2.5406 mL | |
10 mM | 0.1270 mL | 0.6352 mL | 1.2703 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04390399 | Recruiting | Biological: N-803 Drug: Aldoxorubicin HCl |
Pancreatic Cancer | ImmunityBio, Inc. | July 21, 2020 | Phase 2 |
NCT03387085 | Active Recruiting |
Drug: Aldoxorubicin HCl Biological: N-803 |
Triple Negative Breast Cancer | ImmunityBio, Inc. | March 16, 2018 | Phase 1 Phase 2 |
NCT01673438 | Completed | Drug: aldoxorubicin | Advanced Solid Tumor | ImmunityBio, Inc. | July 2012 | Phase 1 |